TIDMSN.
Smith & Nephew Plc
15 November 2017
New RCT demonstrates effectiveness of ALLEVYN LIFE to prevent
the onset of pressure ulcers
15 November 2017
Smith & Nephew plc (LSE:SN, NYSE:SNN), the global medical
technology business, today announces the results of a randomised
controlled trial showing that the addition of ALLEVYN LIFE, Smith
& Nephew's leading multi-layer polyurethane dressing, to a
standard care protocol significantly reduces the onset of pressure
ulcers in elderly patients admitted to hospital for hip
fracture.
Presented at the European pressure ulcer advisory panel annual
meeting 2017, the Effectiveness of Using a New Polyurethane Foam
Multi-layer Dressing in the Sacral Area to Prevent the Onset of
Pressure Ulcer in the Elderly with Hip Fractures. A Pragmatic
Randomized Controlled Trial
http://www.smith-nephew.com/education/resources/video/2017/october/epuap---effectiveness-of-using-a-new-polyurethane-foam-multi-layer-dressing-/
by Professor Cristiana Forni, Head of a research nursing centre,
Rizzoli Orthopaedic Institute, Bologna, Italy, charts the
experience of 359 fragility hip fracture patients aged 65 or over.
These patients were randomly divided into two groups, with some
receiving standard care and others receiving standard care with the
addition of an ALLEVYN LIFE dressing applied to the sacrum.
15.4% of patients receiving standard care developed a pressure
ulcer as opposed to only 4.5% of the group who received the same
care with the addition of ALLEVYN LIFE.
"Hip fractures in the elderly are a serious problem due to the
high rate of mortality and complications such as pressure ulcers,
which occur mainly in the sacral area," said Professor Forni.
"Preventive measures play an important role in increasing quality
of care, reducing health costs and improving the patient's quality
of life. Our research shows that ALLEVYN LIFE is effective at
reducing the rate of pressure ulcers in the sacrum in elderly
patients with hip fracture. The excellent adhesiveness of this
device also enables costs to be kept down."
This new study adds to the growing body of evidence
demonstrating the effectiveness of ALLEVYN LIFE in multi-component
pressure ulcer prevention programmes(1,2,3,4) . ALLEVYN LIFE is
demonstrated to redistribute pressure (in vitro)(5) and can be
lifted and repositioned(6) to allow regular skin inspections.
Prophylactic dressings do not negate the need for thorough and
regular skin assessment and should be used as part of a
comprehensive pressure ulcer prevention protocol.
"Many global experts and professional bodies(7) state
polyurethane foam dressings should be considered for use
prophylactically on bony prominences in anatomical areas subject to
friction and shear" said Dr Andy Weymann, Chief Medical Officer,
Smith & Nephew. "This new research further demonstrates that
ALLEVYN LIFE is a safe and effective preventative measure suited to
be at the heart of a pressure ulcer prevention strategy."
ALLEVYN LIFE has been designed following observational
ethnographic research with patients and clinicians to address unmet
needs in wound management. The dressing has a unique five layer
design incorporating a breathable top layer, hydrocellular foam,
hyper-absorbent lock away core, masking layer, silicone gel
adhesive layer and wide border. ALLEVYN LIFE Sacrum has a unique
tail designed specifically for wounds in the sacral area and fits
around the cleft, to help overcome common problems such as the
dressing tenting.
To learn more about what we do to help reduce pressure ulcer
incidence, please visit www.closertozero.com
- ends -
Enquiries
Media
+44 (0) 1923
Charles Reynolds 477314
Smith & Nephew
Dave Snyder +1 (978) 749-1440
Smith & Nephew
+44 (0) 20 3727
Ben Atwell / Debbie Scott 1000
FTI Consulting
Investors
+44 (0) 20 7960
Ingeborg Øie 2285
Smith & Nephew
References
1. Clarke, B: Positive patient outcomes: The use of a new
silicone adhesive hydrocellular foam dressing for pressure ulcer
prevention and treatment
2. Lisco, C: Evaluation of a new silicone gel-adhesive
hydrocellular foam dressing as part of a pressure ulcer prevention
plan for ICU patients
3. Brindle, T: Preventing sacral pressure ulcer development in the surgical patient population
4. Sammon, M: Reducing Hospital-acquired pressure injuries and
the cost of prevention in the OR and ICU setting
5. Data on File report DS/15/217/R Oct 2015, L. Daubney. Pressure transmission testing
6. Data on File report GMCA-DOF/08-April 2016, A. Rossington.
Product performance of the next generation ALLEVYN LIFE
7. National Pressure Ulcer Advisory Panel, European Pressure
Ulcer Advisory Panel and Pan Pacifi c Pressure Injury Alliance.
Prevention and Treatment of Pressure Ulcers: Clinical Practice
Guideline. Emily Haesler (Ed.) Cambridge Media: Osborne Park,
Western Australia; 2014.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2016 were
almost $4.7 billion. Smith & Nephew is a member of the FTSE100
(LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may or
may not prove accurate. For example, statements regarding expected
revenue growth and trading margins, market trends and our product
pipeline are forward-looking statements. Phrases such as "aim",
"plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
Trademark of Smith & Nephew. Certain marks registered US
Patent and Trademark Office.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAGGGGCGUPMGQC
(END) Dow Jones Newswires
November 15, 2017 03:00 ET (08:00 GMT)
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Smith and Nephew (NYSE:SNN)
Historical Stock Chart
From Sep 2023 to Sep 2024